Adma Biologics reported $-14437000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adma Biologics ADMA:US $ -14.44M 1.14M
Agile Therapeutics AGRX:US -15774000 877K
Alnylam Pharmaceuticals ALNY:US $ -181.68M 35.52M
Biocryst Pharmaceuticals BCRX:US $ -44.58M 15M
China Cord Blood CO:US 160.45M 3.9M
Dynavax Technologies DVAX:US $ 16.07M 12.13M
Kindred Biosciences KIN:US -8544000 622K
Minerva Neurosciences NERV:US $ -7.52M 1.44M
Novavax NVAX:US $ -307.14M 38.68M
Omeros OMER:US $ -18253000 5.76M
Takeda 4502:JP Y 97427M 151125M